Eli Lilly and (LLY) 10-Q2017 Q2 Quarterly report

Filed: 28 Jul 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Adcirca, Amylin, Arzneimittel, Baker, cattle, customary, DACRA, dose, Dual, earliest, Elanco, eleven, equivalent, failure, Florida, footnote, gathering, immunological, interim, KeyBioscience, longer, Ltda, metabolic, Microsoft, Minnesota, month, Nektar, Nipro, platform, procedural, proper, Quimica, receipt, reconstituted, remove, Sherman, Similarly, Stada, superseded, swine, temporarily, UT, Virginia, withdraw

Removed: administratively, bound, cell, challenge, Division, EPO, granting, guarantee, indemnification, indemnify, largely, lodged, Louisiana, lung, manufacture, NSCLC, obtaining, opposition, original, parallel, reversed, subsequently, variability, wholesaler, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

LLY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 12. Statement Re: Computation of Ratio of Earnings to Fixed Charges

ELI LILLY AND COMPANY AND SUBSIDIARIES

(Dollars in millions)



	Six Months Ended June 30,			Years Ended December 31,
	2017			2016			2015			2014			2013			2012
	(Unaudited)
Consolidated pretax income	$	1,321.7		$	3,374.0		$	2,790.0		$	3,000.3		$	5,889.3		$	5,408.2
Interest ⁽¹⁾	128.0			232.9			216.0			187.1			184.2			198.8
Less interest capitalized during the period	(27.8		)	(47.7		)	(54.8		)	(38.3		)	(24.1		)	(21.0		)
Earnings	$	1,421.9		$	3,559.2		$	2,951.2		$	3,149.1		$	6,049.4		$	5,586.0
Fixed charges	$	128.0		$	232.9		$	216.0		$	187.1		$	184.2		$	198.8
Ratio of earnings to fixed charges	11.1			15.3			13.7			16.8			32.8			28.1



⁽¹⁾	Interest is based upon interest expense reported as such in the consolidated condensed statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense.